Nmtc stock forecast for early Q3 2024 shows a modest

NMTC stock forecast for early Q3 2024 shows a modest bullish trend, supported by recent sector-wide gains in specialty communications. Analysts expect the price to hover between $7.80 and $8.50, with volume spikes tied to upcoming earnings reports. Technical indicators suggest a likely breakout above the 50-day moving average. The OneRF platform leverages proprietary multi-contact RF probe technology, allowing precise localization and tailored ablation under temperature-controlled conditions. This innovation aims to improve patient safety, reduce procedural time, and expand NMTC’s footprint in pain management. The FDA clearance also opens doors for future applications across other neurological and pain-related therapies, positioning the company for potential revenue growth as early as late 2025. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Technical traders note NMTC stock forecast trendlines converging toward an ascending triangle pattern, a common bullish signal in price action analysis. If volume exceeds its 30-day average, a breakout could see targets near $9.00 in short-term trades.